Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Optus Pharmaceutical Co. Ltd. (131030:KRX), powered by AI.
Optus Pharmaceutical Co. Ltd. is currently trading at ₩10,800. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Optus Pharmaceutical Co. Ltd. on Alpha Lenz.
Optus Pharmaceutical Co. Ltd.'s P/E ratio is 16.0.
“Optus Pharmaceutical Co. Ltd. trades at a P/E of 16.0 (fair value) with modest ROE of 7.4%. 3Y revenue CAGR of 12.6% highlights clear growth momentum.”
Ask for details →Optus Pharmaceutical Co. Ltd. is a company engaged in the development, manufacturing, and marketing of pharmaceutical products. Its primary function is to provide innovative and effective medications that cater to a wide range of medical needs. Optus Pharmaceutical focuses on both prescription drugs and over-the-counter pharmaceuticals, serving various therapeutic areas such as oncology, cardiovascular diseases, and infectious diseases. With a commitment to research and development, the company aims to introduce breakthrough drugs that enhance patient care and address unmet medical needs. Optus Pharmaceutical plays a significant role in the healthcare sector by collaborating with healthcare professionals, regulatory bodies, and research institutions. Its operations not only contribute to advancements in medical treatments but also have an impact on the pharmaceutical supply chain, affecting distribution channels worldwide. By consistently prioritizing quality and efficacy, Optus Pharmaceutical Co. Ltd. maintains its position as an important player in the global pharmaceutical industry.
“Optus Pharmaceutical Co. Ltd. trades at a P/E of 16.0 (fair value) with modest ROE of 7.4%. 3Y revenue CAGR of 12.6% highlights clear growth momentum.”
Ask for details →